Catalog No.
FHD80810
Species reactivity
Human
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Conjugation
Unconjugated
Target
Cyclic ADP-ribose hydrolase 1, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase, T10, 2'-phospho-cyclic-ADP-ribose transferase, CD38, ADPRC 1, ADP-ribosyl cyclase 1, 2'-phospho-ADP-ribosyl cyclase
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P28907
Applications
FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA0013
Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series., PMID:40528367
Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study., PMID:40518372
CD38-targeted antibody-polymer drug conjugates for enhanced treatment of multiple myeloma., PMID:40516447
PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance., PMID:40512837
CD11b as a diagnostic biomarker of rheumatoid arthritis and as a risk factor of periodontitis: a pilot study., PMID:40512337
Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials., PMID:40501427
High-Risk Genetic Multiple Myeloma: From Molecular Classification to Innovative Treatment with Monoclonal Antibodies and T-Cell Redirecting Therapies., PMID:40497952
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma., PMID:40493883
Daratumumab for Treatment of Acute Antibody-Mediated Rejection in a Pediatric Kidney Transplant Recipient., PMID:40490910
Novel pretransplant desensitization strategies in heart transplantation., PMID:40486117
Antibody-mediated ratiometric delivery of FLT3 and CDK4/6 dual inhibitors for targeted treatment of acute myeloid leukemia., PMID:40482924
Comparative Efficacy and Safety of Daratumumab-Integrated Quadruple Therapy Versus Triple Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis., PMID:40473556
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia., PMID:40472329
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)., PMID:40468805
FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class Exposed, Relapsed or Refractory Multiple Myeloma., PMID:40465403
Targeting B Cells and Plasma Cells in Glomerular Disease., PMID:40465397
Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma., PMID:40453131
Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma., PMID:40453054
A ROS-Responsive Dual-Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T-Cell Acute Lymphoblastic Leukemia., PMID:40448620
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma., PMID:40447948
Targeting CD38 in Antibody-Mediated Rejection., PMID:40444214
Antibody-mediated Rejection - Treatment Standard., PMID:40440205
The efficacy of new drug regimens in treating newly diagnosed high-risk cytogenetic multiple myeloma patients: a systematic literature review and meta-analysis., PMID:40432724
Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen., PMID:40422527
Reduced immune response to SARS-CoV-2 infection in the elderly after 6 months., PMID:40416973
Antibody polymer drug conjugates with increased drug to antibody ratio: CD38-targeting nanomedicines for innovative therapy of relapsed lymphomas., PMID:40409372
Daratumumab monotherapy as a desensitization strategy prior to cardiac transplantation., PMID:40407767
IGM-7354, an immunocytokine with IL-15 fused to an anti-PD-L1 IgM, induces NK and CD8+ T cell-mediated cytotoxicity of PD-L1 positive tumor cells., PMID:40402523
Microbead-based synthetic niches for in vitro expansion and differentiation of human naïve B-cells., PMID:40385534
Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting., PMID:40361170
Relapsed/refractory multiple myeloma: standard of care management of patients in the Gulf region., PMID:40352314
Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM., PMID:40343678
Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma., PMID:40335949
CD38-targeted attenuated interferon alpha immunocytokine activates both innate and adaptive immune cells to drive anti-tumor activity., PMID:40315226
Multiplex immunophenotyping of human acute myeloid leukemia patients revealed single -cell heterogeneity with special attention on therapy sensitive and therapy resistant subpopulations., PMID:40313947
Failure of daratumumab in the treatment of anti-synthetase syndrome: A case report., PMID:40308381
Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies., PMID:40301559
Kinetics of the humoral and cellular immune response up to 1 year from mpox virus infection., PMID:40294869
Peripheral T-cell subset activation in NMDAR encephalitis: Insights into pathogenesis and biomarker potential for disease monitoring., PMID:40288549
Real-World Data on the Efficacy of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma and Amplification 1q., PMID:40282438
Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group., PMID:40271095
Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin-6 receptor overexpression., PMID:40259818
Desensitization With Proteasome Inhibition and Costimulation Blockade Modulates the Xenoreactive Humoral Response in Nonhuman Primate Xenotransplantation., PMID:40259710
Targeting CD38 immunometabolic checkpoint improves metabolic fitness and cognition in a mouse model of Alzheimer's disease., PMID:40254603
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells., PMID:40245922
The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse., PMID:40241199
Multiple Myeloma Experiences and Preferences: A Mixed Methods Study of Patients and Care Partners in the United States., PMID:40230459
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma., PMID:40225701
Correction: Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma., PMID:40214176
[The highlights of nephrology in 2024]., PMID:40208671
For research use only. Not for human or drug use.
